Shandong Boan Biotech

Boan Biotech is a fully integrated biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic antibodies. As a subsidiary of Luye Pharma Group, the company maintains a strategic focus on oncology, metabolism, ophthalmology, and immunology. Its commercial portfolio includes marketed biosimilars such as Boyounuo (bevacizumab) and Boyoubei (denosumab), which have established a strong market presence in China. Beyond biosimilars, Boan is advancing a robust pipeline of innovative biologics, including bispecific antibodies and antibody-drug conjugates (ADCs). The company leverages proprietary technology platforms like BA-HiMab, a human antibody transgenic mouse platform, to accelerate drug discovery. With large-scale GMP manufacturing facilities and a comprehensive R&D infrastructure, Boan Biotech is positioned as a leading player in the Chinese biopharmaceutical sector.